We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
Read MoreHide Full Article
AveXis, Inc. was a big mover last session, as the company saw its shares rise above 15% on the day. The upside was due to continuation of the rally triggered by the announcement of Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 41% in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Is AVXS going up? Or down? Predict to see what others think: Up or Down
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
AveXis, Inc. was a big mover last session, as the company saw its shares rise above 15% on the day. The upside was due to continuation of the rally triggered by the announcement of Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 41% in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
AveXis currently carries a Zacks Rank #3 (Hold).
AveXis, Inc. Price
AveXis, Inc. Price | AveXis, Inc. Quote
A better-ranked stock in the Medical – Biomedical and Genetics industry is Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AVXS going up? Or down? Predict to see what others think: Up or Down
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>